跳到正文

#企业/市场

今日 47 条
10月13日周二
  1. GEN 生物工程新闻62

    Caribou 寻求战略选择,股价一周暴跌 62% 并暂停两款异体 CAR-T 试验

    Caribou Biosciences 宣布评估战略选择,计划大幅裁员并暂停 vispacabtagene regedleucel(vispa-cel)和 CB-011 两款异体 CAR-T 的临床试验,股价一周内下跌 62%。

    推荐理由:Caribou 在现金承压与同类竞争加剧下停止两款异体 CAR-T 试验并寻求战略选择,可观察异体细胞治疗当前的融资处境。

  2. Pharmaphorum42

    Brent Saunders 再次卸任 Bausch + Lomb CEO,Thomas Appio 临时代任

    Brent Saunders 与董事会达成一致,即刻卸任 Bausch + Lomb CEO,由董事长 Thomas Appio 临时代任,后者同时担任母公司 Bausch Health 的 CEO。Saunders 于 2023 年回归,主导以加大眼科药物投入为核心的转型计划。此前该公司青光眼候选药 BL1107 的 3 期试验失败,该药曾被预期年销售额可达 8 亿美元。

  3. BioPharma Dive62

    Bausch + Lomb更换CEO,默沙东公布眼药remigromig数据

    Bausch + Lomb宣布董事会主席Thomas Appio即刻出任临时CEO,接替Brent Saunders,双方称是“共同同意”其离任。默沙东公布其试验性眼药remigromig的详细数据,显示与增殖性糖尿病视网膜病变相关的不良事件发生率在6.7%和6.1%(依剂量而定),而对照药Lucentis为0.9%,约5%的受试者停药。

    推荐理由:汇总了Bausch + Lomb换帅、默沙东眼药安全性数据及安进/阿斯利康Tezspire三期结果等多条动态。

  4. BioPharma Dive47

    帕金森细胞疗法开发商 Aspen Neuroscience 申请赴纳斯达克上市

    帕金森细胞疗法开发商 Aspen Neuroscience 于 10 月 9 日提交注册文件,计划登陆纳斯达克,股票代码为 ASPE。其最领先疗法 sasineprocel(ANPD001)将患者自身细胞重编程为产生多巴胺的神经元,已完成早期临床试验,正进入后期测试。公司自成立以来已融资约 3.47 亿美元,2025 年净亏损 6200 万美元,注册文件称现有资金不足以支撑未来一年运营。

10月12日周一
  1. Matthew Herper8

    有趣的数据。

    引用Mike Rea@ThenIf_

    Lipitor, the best-selling drug of its era, made less than $1bn in its first 12 months on sale. Which drug had the best first year ever? My new positioning book tells the story of what the first 12 months tell you... The industry studies these launches for lessons in execution, when most of what they share is timing against a queue nobody built. https://lnkd.in/p/e5pPxpD6

  2. BioPharma Dive62

    Evaluate:2026 至 2032 年逾 5000 亿美元处方药销售面临专利到期风险

    Evaluate 与 Norstella 的预测数据显示,2026 至 2032 年全球有超过 5000 亿美元的处方药销售可能因仿制药竞争面临风险,风险并非集中在单一年份。

    推荐理由:Evaluate 数据把 2026 至 2032 年专利到期风险拆到各年与各公司,读者可据此看清压力分布与药企的 BD 应对节奏。

  3. Pharmaceutical Technology22

    Perceptive与Nucleus达成非独家战略合作,支持放射性药物开发

    Perceptive Discovery与Nucleus RadioPharma宣布建立非独家战略合作,帮助放射性药物开发者从靶点验证推进至临床生产。双方将在开发管线各阶段互相推荐合格客户机会,并设立联合治理架构,同时保持各自独立运营。合作聚焦减少从临床前成像到GMP生产过渡中的时间、成本和运营摩擦。

  4. A股药企公告(东财)8

    药明康德发布H股公告

    药明康德发布H股公告,相关数据来自东方财富Choice数据。东方财富网声明该信息仅用于传播更多信息,与本站立场无关,不保证其准确性、真实性、完整性、有效性、及时性、原创性等,且不构成任何投资建议。

10月11日周日
10月10日周六
  1. Adam Feuerstein ✡️22

    Adam Feuerstein 认同 Peter Kolchinsky 的观点:市场应朝推出相对低价、低剂量的非处方 GLP-1 方向发展,用于减重或体重增加预防。

    引用Peter Kolchinsky@PeterKolchinsky

    I think the biggest market pharma will ever tackle will actually be weight gain PREVENTION. And the dynamics of this market are going to be very different from the medicalized weight loss market and require better, more convenient products. The race for that market has only just begun. We helped to pivot one of our companies, Terrestrial, to work in prevention (as well as weight loss), and their clinical progress now makes me comfortable sharing our thesis for the weight gain prevention space. They have a needle-free, room-temp stable microneedle patch where the microneedles are made of semaglutide. Apply it for a few min, the base of the needles dissolves leaving drug under the skin, and you can then throw away the patch. That’s the weekly dose. No sharps containers. Once drug is under skin, it behaves very similarly to regularly injected semaglutide. 505b2 path to market is derisked by all existing data on sema. But Terrestrial isn’t stopping at just getting approved for all same indications as sema. It’s also gunning to get it OTC and get weight gain prevention on the label, legitimizing what today is a common off-label use (so common that South Park parodied it). From a societal value, there may not be any single medical breakthrough that rivals what a needle-free, OTC QW GLP-1 can offer to humanity. Excess weight leads to so much disability, disease, cost, lost productivity, and early mortality. Doesn’t make sense for people to have to gain weight to then get help losing it. Makes more sense for them to get help quieting the hunger noise (drive to eat) so they can avoid gaining weight in the first place. Have doubts? No problem. Read the article and then decide. The key insight here is that an OTC needle-free GLP-1 is not simply some late comer to a mature category but actually the beginning of an entirely new market that is so large that it would be worth any consumer-focused company to pay attention and for any standard pharma to consider what it would take to pivot into this space. And if you have never experienced how a GLP-1 can quiet hunger noise, you’ll have a harder time relating. Young people with fast metabolisms will likely miss this. But someday they will say “holy crap, I get it!”. 60% of Americans are overweight or obese… the battle against weight gain is one most people are destined to lose without help. 3B people around the world are overweight/obese. This is a giant global market at even very low unit prices (eg $25/month). Enjoy the read. Godspeed Terrestial! The RA Capital team is really proud to support you.